Drug intelligence / Profile preview

Pinggan Yuyin Qingre Fang

Development stage: Preclinical
Administration: Oral

Overview

Pinggan Yuyin Qingre Fang (PGYYQR) is a Traditional Chinese Medicine (TCM) herbal formula investigated for the treatment of dry eye disease (DED) associated with meibomian gland dysfunction (MGD). It is specifically indicated for patients presenting with the TCM pattern of 'hyperactivity of Yang due to Yin deficiency.' Administered in granule form, the formula's therapeutic effects are linked to the modulation of the interleukin-17/nuclear factor kappa B (IL-17/NF-κB) signaling pathway, which helps suppress ocular surface inflammation. Research on this formula, including network pharmacology and stratified randomized controlled trials, has been published in academic journals such as the Journal of Traditional Chinese Medicine (2023).

Other names: 平肝育阴清热方PGYYQR

Targets

NF-κBIL-17A (Interleukin-17A)

Beyond the preview

Go deeper on Pinggan Yuyin Qingre Fang.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pinggan Yuyin Qingre Fang.

Explore the full profile